SCHEMBL26075330

SCHEMBL26075330

COCCOc1ccc(-c2ccc(-c3cc(C=O)c4cc(F)ccc4n3)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 4/20 0.41
▸ SQOR Q9Y6N5 1/20 0.40
▸ TNKS O95271 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ TNKS2 Q9H2K2 1/20 0.39
▸ DHODH Q02127 6/20 0.39
▸ MIF P14174 1/20 0.38
▸ PRKAB2 O43741 1/20 0.37
▸ PRKAG1 P54619 1/20 0.37
▸ PRKAA2 P54646 1/20 0.37
▸ PRKAA1 Q13131 1/20 0.37
▸ PRKAG3 Q9UGI9 1/20 0.37
▸ PRKAG2 Q9UGJ0 1/20 0.37
▸ PRKAB1 Q9Y478 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CHEK2 O96017 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075343 0.91 PLA2G2A (0.39) PLA2G2ADHODHMEN1KMT2AKCNH2
SCHEMBL26075352 0.91 DHODH (0.45) PLA2G2ADHODHPDE10A
SCHEMBL26075350 0.91 PLA2G2A (0.44) PLA2G2ADHODHMEN1KMT2AKCNH2
SCHEMBL26075327 0.89 SQOR (0.42) PLA2G2ASQORTNKSPARP1TNKS2
SCHEMBL23590337 0.85 DHODH (0.57) PLA2G2ADHODHPRKAB2PRKAG1PRKAA2
SCHEMBL26075357 0.81 PLA2G2A (0.42) PLA2G2ADHODHPDE10A
SCHEMBL26075362 0.80 PLA2G2A (0.41) PLA2G2ADHODHPDE10A
SCHEMBL26075374 0.80 TP53 (0.36) PLA2G2ADHODHMEN1KMT2AKCNH2
SCHEMBL26075339 0.80 DHODH (0.39) PLA2G2ADHODHKCNH2HRH3PDE10A
SCHEMBL26075237 0.80 PLA2G2A (0.44) PLA2G2ADHODHKCNH2HRH3PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PLA2G2A 1679/4885SQOR 255/4885TNKS 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback